actin related protein 2/3 complex subunit 1BGenealiases: ARC41 · IMD71 · PLTEID · p40-ARC · p41-ARC
Q-omics provides the consensus-scored ARPC1B profile across patient tissues and cancer cell-line models. ARPC1B expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ARPC1B is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ARPC1B protein abundance shows 33,021 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, HNSC, and LSCC as cancer lineages where ARPC1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARPC1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARPC1B survival associations across molecular data types. ARPC1B RNA expression shows survival associations in the most cancer types (29), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARPC1B RNA expression–survival associations across cancer types. High ARPC1B expression shows unfavorable associations in UVM, ACC, KIRC, LGG, LIHC and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ARPC1B RNA expression.
This table summarizes ARPC1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ARPC1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARPC1B shows higher tumor expression in HNSC, KIRC, KIRP, COAD, LIHC and STAD. The HNSC box plot shows higher ARPC1B RNA expression in tumor versus normal tissue (log2 FC = +2.246, t-test p < 0.001).
This table shows molecular features associated with ARPC1B in patient tissues and cancer cell lines. In patient samples, ARPC1B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ARPC1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
